AI-driven discovery of antiretroviral drug bictegravir and etravirine as inhibitors against monkeypox and related poxviruses

Monkeypox virus (MPXV) caused the 2022-2023 global mpox and the concurrent outbreaks in Africa, disproportionately affecting immunocompromised individuals such as people living with HIV. With no approved treatment available, we developed a robust artificial intelligence (AI) pipeline for discovering broad-spectrum poxvirus inhibitors that target the viral DNA polymerases. Among the identified leading candidates, we found that the clinically used antiretroviral drugs bictegravir and etravirine potently inhibit MPXV clade Ia, Ib and IIb infections in human intestinal and skin organoids. The broad anti-poxvirus activities of bictegravir and etravirine were further demonstrated against infections of other Orthopoxviruses such as vaccinia virus and cowpox virus. These findings support the repurposing of bictegravir and etravirine for treating mpox, especially for patients co-infected with HIV, warranting follow-up clinical investigation. The established AI pipeline and our antiviral drug discovery strategies bear major implications for responding to the ongoing mpox emergency and preparing for future poxvirus epidemics.

Authors

Institutions

Publication Details

Journal
Communications Biology
Published
2025-12-02
DOI
https://doi.org/10.1038/s42003-025-09129-x
Citations
1
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
1.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

AI-driven discovery of antiretroviral drug bictegravir and etravirine as inhibitors against monkeypox and related poxviruses

Tunca Doğan, Marcel J. C. Bijvelds, Rory D. de Vries, Nadia A. Sam‐Agudu et al.
1 citations
Communications Biology
Poxvirus research and outbreaks
1.04
article

AI-driven discovery of antiretroviral drug bictegravir and etravirine as inhibitors against monkeypox and related poxviruses

Tunca Doğan, Marcel J. C. Bijvelds, Rory D. de Vries, Nadia A. Sam‐Agudu, Wenshi Wang, Qiuwei Pan, Xin Wang, Abdurrahman Olğaç, Atabey Ünlü, Elif Çevrim, Luca M. Zaeck, Karine Raymond, Pengfei Li, Liping Wu, Yining Wang, Dewy Mae Offermans, Myrthe P. Flesseman
article en
1 citations

Abstract

Monkeypox virus (MPXV) caused the 2022-2023 global mpox and the concurrent outbreaks in Africa, disproportionately affecting immunocompromised individuals such as people living with HIV. With no approved treatment available, we developed a robust artificial intelligence (AI) pipeline for discovering broad-spectrum poxvirus inhibitors that target the viral DNA polymerases. Among the identified leading candidates, we found that the clinically used antiretroviral drugs bictegravir and etravirine potently inhibit MPXV clade Ia, Ib and IIb infections in human intestinal and skin organoids. The broad anti-poxvirus activities of bictegravir and etravirine were further demonstrated against infections of other Orthopoxviruses such as vaccinia virus and cowpox virus. These findings support the repurposing of bictegravir and etravirine for treating mpox, especially for patients co-infected with HIV, warranting follow-up clinical investigation. The established AI pipeline and our antiviral drug discovery strategies bear major implications for responding to the ongoing mpox emergency and preparing for future poxvirus epidemics.

Communications BiologyVol. 8(1)
Shenyang Pharmaceutical University (CN), University of Cape Coast (GH), Inserm (FR), Xuzhou Medical College (CN), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Leiden University Medical Center (NL), Erasmus MC (NL), CEA Grenoble (FR), Institute of Human Virology (NG), University of Minnesota Medical Center (US), Hacettepe University (TR), Université Grenoble Alpes (FR), Erasmus University Rotterdam (NL), Gazi University (TR)
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Public Health Agency, Institut National de la Santé et de la Recherche Médicale, ZonMw, Novo Nordisk, Novo Nordisk Fonden, Folkhälsomyndigheten, Robert Koch Institut
Openalex Percentile: Top 18%
Poxvirus research and outbreaks
1.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.